Depression News and Research

Latest Depression News and Research

CAMFT encourages people to focus on emotional health in 2010

While most New Year's resolutions revolve around changing your outward appearance by losing weight or hitting the gym, the California Association of Marriage and Family Therapists (CAMFT) encourages people to rethink their New Year's resolutions this year to focus inward on their emotional health in 2010.

29 Dec 2009

Hunger hormone can intensify high-fat food consumption

The premise that hunger makes food look more appealing is a widely held belief - just ask those who cruise grocery store aisles on an empty stomach, only to go home with a full basket and an empty wallet.

28 Dec 2009

Interdisciplinary approach essential for treating men’s' sexual dysfunction

Modern, couple-oriented treatment for male sexual dysfunction takes the psychosocial aspects of sex into account, as well as focussing on the purely physical aspects of the problem.

24 Dec 2009

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

2009 saw exciting research progress, unprecedented opportunities on the horizon, and more scientists than ever working on resolving important questions. Despite the year's economic and financial challenges, the National Multiple Sclerosis Society continues to propel research forward to end MS. In 2009 the Society provided over $33.5 million to support 345 new and ongoing projects in its research portfolio, plus $1.5 million for Fast Forward, the Society's drug development subsidiary which continues to attract new funding streams.

23 Dec 2009

Postnatal depression treatments are not cost effective, say York researchers

Routine screening for postnatal depression in primary care - as recommended in recent guidance from the National Institute for Health and Clinical Excellence (NICE) - does not appear to represent value for money for the NHS, researchers at the University of York have concluded.

23 Dec 2009

Back pain problems continue to rise in U.S.

The Bonati Spine Institute, the leader in minimally invasive laser spine surgery, reports the results of studies that Americans are increasingly reporting back pain and spending more on back pain, but cautions consumers to carefully research the experience and the surgical outcome results when choosing their spine team.

23 Dec 2009

Magnetic stimulation therapy can treat depression

Magnetic stimulation therapy can beat depression when medication and therapy haven't worked, according to the December issue of Mayo Clinic Health Letter.

23 Dec 2009

Depressed patients are unable to sustain positive emotions, says study

A new study at the University of Wisconsin-Madison suggests that depressed patients are unable to sustain activity in brain areas related to positive emotion.

22 Dec 2009

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Neurocrine Biosciences, Inc. today announced their highly selective vesicular monoamine transporter 2 (VMAT2) inhibitor, NBI-98854, will be advanced in clinical development.

21 Dec 2009

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

Intra-Cellular Therapies, Inc. (ITI) announced at a recent conference on neuropsychiatric diseases the results from a recently completed Phase I clinical study demonstrating ITI-007, the Company's lead antipsychotic drug, interacts with important targets in the living human brain. These key targets are critical to drug action in many neuropsychiatric and related disorders.

21 Dec 2009

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

‘Tis the season for celebrating with family and friends -- and searching for those perfect gifts. CIGNA suggests adding another item to the top of the holiday “To Do” list: Be sure to take needed medications to stay healthy this holiday season and into the New Year.

19 Dec 2009

GSK receives European CHMP positive opinion for Revolade

Ligand Pharmaceuticals Incorporated today announced that its partner GlaxoSmithKline has received a positive opinion for Revolade® (eltrombopag/Promacta®) from the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) for the oral treatment of thrombocytopenia (reduced platelet count) in adults with the blood disorder chronic immune (idiopathic) thrombocytopenic purpura (ITP).

18 Dec 2009

A program to reduce depression and isolation among the elderly during holiday season

MyWay Village, the first senior-focused technology company to help seniors get online in an easy and social way by combining access to simplified technology with personal training and support, today announced that their Connected Living program is reducing depression and feelings of isolation especially during the holiday season within senior communities where the company's programs are being offered.

18 Dec 2009

Researchers identify risk factors for major depression in elderly patients

University of Rochester Medical Center researchers have pinpointed the prime factors identifying which elderly persons are at the highest risk for developing major depression.

18 Dec 2009

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Researchers have developed a novel animal model showing that four commonly used chemotherapy drugs disrupt the birth of new brain cells, and that the condition could be partially reversed with the growth factor IGF-1.

18 Dec 2009

Cannabis can cause depression and anxiety in teenagers

Canadian teenagers are among the largest consumers of cannabis worldwide. The damaging effects of this illicit drug on young brains are worse than originally thought, according to new research by Dr. Gabriella Gobbi, a psychiatric researcher from the Research Institute of the McGill University Health Centre. The new study, published in Neurobiology of Disease, suggests that daily consumption of cannabis in teens can cause depression and anxiety, and have an irreversible long-term effect on the brain.

18 Dec 2009

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Somaxon Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the in-licensing, development and commercialization of proprietary branded pharmaceutical products and late-stage product candidates for the treatment of diseases and disorders in the central nervous system therapeutic area, today stated that it is scheduled to meet with the U.S. Food and Drug Administration (FDA) on January 20, 2010 to discuss the New Drug Application (NDA) for Silenor® (doxepin) for the treatment of insomnia.

18 Dec 2009

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Neurocrine Biosciences, Inc. today reported that it has entered into a privately negotiated transaction to sell an aggregate of 4,784,689 primary shares of its common stock to affiliates of Venrock at a price of $2.09 per share, raising aggregate gross proceeds to Neurocrine of approximately $10 million. Neurocrine expects the financing to close on or about December 22, 2009, subject to customary closing conditions.

17 Dec 2009

Tips for healthy living for the year ahead

Whether you are a vegetarian, vegan, carnivore or pescetarian, vegetables should be a central part of your diet. Often referred to as a "protective food," dark green foods provide essential vitamins and nutrients to your body that protect you from many of life's worst diseases.

17 Dec 2009

ASA offers practical ways for sufferers to take active role in treatment of pain

Whether the result of injury, illness or a chronic condition, 70 million Americans experience pain annually. The individual pain sufferer may experience a diminished quality of life, lack of mobility and added stress.

17 Dec 2009

Depression News and Research

Latest Depression News and Research

CAMFT encourages people to focus on emotional health in 2010

Hunger hormone can intensify high-fat food consumption

Interdisciplinary approach essential for treating men’s' sexual dysfunction

National MS Society calls for grant applications to examine the impact of CCSVI hypothesis

Postnatal depression treatments are not cost effective, say York researchers

Back pain problems continue to rise in U.S.

Magnetic stimulation therapy can treat depression

Depressed patients are unable to sustain positive emotions, says study

Neurocrine to advance its NBI-98854 VMAT2 Inhibitor into a multiple repeated dose Phase 1 study

Intra-Cellular Therapies announces results of its ITI-007 antipsychotic drug Phase I study

CIGNA suggests the 'To Do' list to stay healthy during this holiday season

GSK receives European CHMP positive opinion for Revolade

A program to reduce depression and isolation among the elderly during holiday season

Researchers identify risk factors for major depression in elderly patients

Four commonly used chemotherapy drugs disrupt birth of new brain cells, shows study

Cannabis can cause depression and anxiety in teenagers

Somaxon Pharmaceuticals to meet FDA to discuss the NDA for Silenor for insomnia treatment

Neurocrine Biosciences to sell 4,784,689 shares of common stock to Venrock affiliates

Tips for healthy living for the year ahead

ASA offers practical ways for sufferers to take active role in treatment of pain

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Depression News and Research

Latest Depression News and Research

Small solutions for big problems in drug discovery and delivery

Professor Nancy Ip: Pioneering New Paths in Neurodegenerative Therapy

Utilizing process Raman in optimizing cultivated meat production

Newsletters you may be interested in